ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
New data independently confirms and extends laboratory findings and expands safety profile of ATH434
August 04, 2020Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for presentation at the 2020 Internati -
Jardiance® (empagliflozin) analysis reinforces established safety profile
July 10, 2017An analysis of pooled safety data from 15 studies plus 4 extension studies involving more than 12,500 adults with type 2 diabetes demonstrated treatment with Jardiance® (empagliflozin) tablets (10 mg or 25 mg) was well tolerated, with no imbalance in lowe
Pharma Sources Insight January 2025
